Innoviva Inc
Change company Symbol lookup
Select an option...
INVA Innoviva Inc
IBM International Business Machines Corp
COTY Coty Inc
KURA Kura Oncology Inc
UBQU Ubiquitech Software Corp
VZ Verizon Communications Inc
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including, RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO and ELLIPTA. RELVAR/BREO is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS) and fluticasone furoate (FF). ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI. TRELEGY ELLIPTA a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Price
Delayed
$16.57
Day's Change
-0.1082 (-0.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
16.94
Day's Low
16.57
Volume
(Light)

Today's volume of 187,272 shares is on pace to be much lighter than INVA's 10-day average volume of 643,002 shares.

187,272

Company Profile

Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including, RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO and ELLIPTA. RELVAR/BREO is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS) and fluticasone furoate (FF). ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI. TRELEGY ELLIPTA a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Valuation Ratios

Price/Earnings (TTM)
5.27x
Price/Sales (TTM)
3.05x
Price/Book (MRQ)
2.84x
Price/Cash Flow (TTM)
2.77x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

November 2021
Current Month
9.5M
Previous Month
9.1M
Percent of Float
13.79%
Days to Cover
11.1655 Days

Share Information

INVA is in a share class of common stock
Float
68.9M
Shares Outstanding
69.5M
Institutions Holding Shares
278
97.05%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Odysseas D. KostasChmn.
  • Pavel RaifeldCEO
  • Marianne Y. ZhenCAO
  • George W. Bickerstaff
  • Deborah L. Birx

Address

  • 1350 Old Bayshore Highway, Suite 400
  • Burlingame, CA 94010
  • Phone: (650) 238-9600
  • Fax: (302) 655-5049
  • https://www.inva.com/

Insider Trading

During the most recent quarter, 4K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.